These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2357863)

  • 41. Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes.
    Masubuchi Y; Kagimoto N; Narimatsu S; Fujita S; Suzuki T
    Drug Metab Dispos; 1993; 21(6):1012-6. PubMed ID: 7905378
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ventricular electrophysiology of quinidine-propranolol combinations in the dog heart.
    Korte DW; Nash CB
    J Pharmacol Exp Ther; 1976 May; 197(2):452-7. PubMed ID: 1271287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine.
    Pfandl B; Mörike K; Winne D; Schareck W; Breyer-Pfaff U
    Xenobiotica; 1992 Jun; 22(6):721-30. PubMed ID: 1441595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
    Kessler KM; Humphries WC; Black M; Spann JF
    Am Heart J; 1978 Nov; 96(5):627-35. PubMed ID: 263396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.
    Ujhelyi MR; O'Rangers EA; Fan C; Kluger J; Pharand C; Chow MS
    Clin Pharmacol Ther; 1993 Jan; 53(1):38-48. PubMed ID: 8422740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole.
    Ching MS; Elliott SL; Stead CK; Murdoch RT; Devenish-Meares S; Morgan DJ; Smallwood RA
    Aliment Pharmacol Ther; 1991 Oct; 5(5):523-31. PubMed ID: 1793783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
    Kharasch ED; Hoffer C; Whittington D; Sheffels P
    Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of some beta adrenergic blocking agents and phenytoin on potentiation of quinidine antiarrhythmic activity in the mouse.
    Lawson JW
    Arch Int Pharmacodyn Ther; 1984 Jul; 270(1):106-15. PubMed ID: 6149731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of 4 antiarrhythmic drugs on sinoatrial conduction time in isolated and blood-perfused dog atria.
    Shimotori M; Kobayashi M; Chiba S
    Arch Int Pharmacodyn Ther; 1984 Jan; 267(1):67-79. PubMed ID: 6721625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol.
    Weissenburger J; Davy JM; Chézalviel F; Ertzbischoff O; Poirier JM; Engel F; Lainée P; Penin E; Motté G; Cheymol G
    J Pharmacol Exp Ther; 1991 Nov; 259(2):871-83. PubMed ID: 1941633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH; Wood AJ
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human hepatic microsomes.
    Marre F; Fabre G; Lacarelle B; Bourrie M; Catalin J; Berger Y; Rahmani R; Cano JP
    Drug Metab Dispos; 1992; 20(2):316-21. PubMed ID: 1352227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
    Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Itraconazole increases plasma concentrations of quinidine.
    Kaukonen KM; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Nov; 62(5):510-7. PubMed ID: 9390107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of a low dose of quinidine on the disposition of flecainide in healthy volunteers.
    Munafo A; Buclin T; Tuto D; Biollaz J
    Eur J Clin Pharmacol; 1992; 43(4):441-3. PubMed ID: 1451729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation.
    Guirguis MS; Jamali F
    J Pharm Sci; 2003 May; 92(5):1077-84. PubMed ID: 12712428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Daily JP; Harmatz JS; Shader RI
    J Pharm Sci; 1998 Oct; 87(10):1184-9. PubMed ID: 9758674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
    Steiner E; Dumont E; Spina E; Dahlqvist R
    Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.